Key result
Rivaroxaban linked to lower SSE and major bleeding versus warfarin in obese NVAF patients.
Why the study?
Does rivaroxaban reduce the risk of stroke, systemic embolism, and major bleeding compared to warfarin in obese patients with nonvalvular atrial fibrillation?
Does rivaroxaban reduce the risk of stroke, systemic embolism, and major bleeding compared to warfarin in obese patients with nonvalvular atrial fibrillation?
In obese patients with nonvalvular atrial fibrillation, rivaroxaban is associated with lower risks of stroke, systemic embolism, and major bleeding compared to warfarin.
May support rivaroxaban over warfarin in obese NVAF; leaves open need for RCT confirmation.
Among obese NVAF patients, prescription of rivaroxaban was associated with a reduced risk of SSE and major bleeding compared to warfarin, which remained consistent across BMI classes.
No takes yet. Share an insight, caveat, or question.
Costa et al. (2020) studied this question. Rivaroxaban was associated with a reduced risk of SSE and major bleeding compared to warfarin in obese patients with nonvalvular atrial fibrillation across all BMI classes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: